Literature DB >> 1551980

Multicenter evaluation of five commercial rubella virus immunoglobulin G kits which report in international units per milliliter.

W Dimech1, A Bettoli, D Eckert, B Francis, J Hamblin, T Kerr, C Ryan, I Skurrie.   

Abstract

In a multicenter study, the consistency of international units expressed by five commercially available rubella virus immunoglobulin G kits was evaluated. The linearity and within-run and between-run precision were determined for each kit. All kits demonstrated good linearity and had within-run and between-run precision coefficients of variation ranging from 5.1 to 21.7% and from 9.5 to 51.0%, respectively. To compare the international units expressed, the results from 40 samples tested in duplicate were compared with the results of a reference enzyme immunoassay calibrated with World Health Organization international standard serum and a hemagglutination inhibition test. The results of the kits were plotted against those of the reference tests, and linear regression analysis was applied. The Pearson correlation coefficient ranged from 0.64 to 0.75 when the commercial kit results were compared with those of the reference enzyme immunoassay, indicating only a moderate degree of correlation. Therefore, the international units expressed by the commercial kits are insufficiently consistent to be of practical use in diagnostic clinical microbiology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551980      PMCID: PMC265124          DOI: 10.1128/jcm.30.3.633-641.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  The Abbott IMx automated benchtop immunochemistry analyzer system.

Authors:  M Fiore; J Mitchell; T Doan; R Nelson; G Winter; C Grandone; K Zeng; R Haraden; J Smith; K Harris
Journal:  Clin Chem       Date:  1988-09       Impact factor: 8.327

2.  Incorrect least-squares regression coefficients in method-comparison analysis.

Authors:  P J Cornbleet; N Gochman
Journal:  Clin Chem       Date:  1979-03       Impact factor: 8.327

3.  Use and interpretation of common statistical tests in method-comparison studies.

Authors:  J O Westgard; M R Hunt
Journal:  Clin Chem       Date:  1973-01       Impact factor: 8.327

4.  Better laboratory evaluations of instruments and kits are required.

Authors:  C G Fraser; R Singer
Journal:  Clin Chem       Date:  1985-05       Impact factor: 8.327

5.  Problems in determining immune status in borderline specimens in an enzyme immunoassay for rubella immunoglobulin G antibody.

Authors:  R S Steece; M S Talley; M R Skeels; G A Lanier
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

6.  Characteristics of statistical parameters used to interpret least-squares results.

Authors:  R B Davis; J E Thompson; H L Pardue
Journal:  Clin Chem       Date:  1978-04       Impact factor: 8.327

7.  A recommended scheme for the evaluation of kits in the clinical laboratory.

Authors:  I W Percy-Robb; P M Broughton; R D Jennings; J J McCormack; D W Neill; R A Saunders; M Warner
Journal:  Ann Clin Biochem       Date:  1980-09       Impact factor: 2.057

8.  A simple method for detecting antibodies to rubella.

Authors:  A Voller; D E Bidwell
Journal:  Br J Exp Pathol       Date:  1975-08

9.  Evaluation of microparticle enzyme immunoassays for immunoglobulins G and M to rubella virus and Toxoplasma gondii on the Abbott IMx automated analyzer.

Authors:  L E Schaefer; J W Dyke; F D Meglio; P R Murray; W Crafts; A C Niles
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

10.  Evaluation of rubella immune status by three commercial enzyme-linked immunosorbent assays.

Authors:  P R Field; D W Ho; A L Cunningham
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

View more
  9 in total

1.  Basic problems of serological laboratory diagnosis.

Authors:  W Fierz
Journal:  Mol Biotechnol       Date:  1999-12-01       Impact factor: 2.695

2.  Results of continuous monitoring of the performance of rubella virus IgG and hepatitis B virus surface antibody assays using trueness controls in a multicenter trial.

Authors:  Tamara Kruk; Sam Ratnam; Jutta Preiksaitis; Allan Lau; Todd Hatchette; Greg Horsman; Paul Van Caeseele; Brian Timmons; Graham Tipples
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

3.  Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter.

Authors:  Wayne Dimech; Lena Panagiotopoulos; Barbara Francis; Nicholas Laven; Joan Marler; David Dickeson; Tony Panayotou; Kim Wilson; Robyn Wootten; Elizabeth M Dax
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

4.  Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays.

Authors:  Wayne Dimech; Nilukshi Arachchi; Jingjing Cai; Terri Sahin; Kim Wilson
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

5.  Where to Now for Standardization of Anti-Rubella Virus IgG Testing.

Authors:  Wayne Dimech
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

6.  Multicenter evaluation of a novel quantification method for rubella and toxoplasmosis antibodies.

Authors:  B Martens-Düring; H D Dopatka
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

7.  High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers.

Authors:  Nathaniel D Lambert; V Shane Pankratz; Beth R Larrabee; Adaeze Ogee-Nwankwo; Min-hsin Chen; Joseph P Icenogle; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

Review 8.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

9.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.